Osimertinib (dimesylaat) (standaard)

Osimertinib (dimesylate) (Standard) is the analytical standard of Osimertinib (dimesylate) . This product is intended for research and analytical applications. Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.

2070014-82-1

12352100

EGFR; Reference Standards

JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK

Cancer

CS(=O)(O)=O.C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O

C30H41N7O8S2

691.82

[1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4 (9) :1046-61.|[2]Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistancemutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57 (20) :8249-67.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-79077R/

Reference Standards